Jump to content

Modafinil: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
"eugeroic" is a non-professional neologism
m unwlk double
Line 21: Line 21:
| excretion = Urine (as metabolites)
| excretion = Urine (as metabolites)
}}
}}
'''Modafinil''' is a [[stimulant]] drug generally prescribed to treat [[narcolepsy]], made by the pharmaceutical company [[Cephalon]]. It is not a typical [[stimulant]] and is often described as a "wakefulness promoting agent". The drug is sometimes prescribed [[off-label use|off-label]] for [[Attention-deficit hyperactivity disorder|Attention-Deficit Hyperactivity Disorder]] (ADHD). In mass-media advertisements and websites, Cephalon markets the drug for improving "alertness" and reducing [[excessive daytime sleepiness]].
'''Modafinil''' is a [[stimulant]] drug generally prescribed to treat [[narcolepsy]], made by the pharmaceutical company [[Cephalon]]. It is not a typical stimulant and is often described as a "wakefulness promoting agent". The drug is sometimes prescribed [[off-label use|off-label]] for [[Attention-deficit hyperactivity disorder|Attention-Deficit Hyperactivity Disorder]] (ADHD). In mass-media advertisements and websites, Cephalon markets the drug for improving "alertness" and reducing [[excessive daytime sleepiness]].


== Commercial trade names ==
== Commercial trade names ==

Revision as of 21:13, 9 April 2008

Modafinil
Clinical data
Pregnancy
category
  • C
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding60%
MetabolismHepatic, including CYP3A4 and other pathways
Elimination half-life8–18 hours
ExcretionUrine (as metabolites)
Identifiers
  • 2-benzhydrylsulfinylethanamide
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.168.719 Edit this at Wikidata
Chemical and physical data
FormulaC15H15NO2S
Molar mass273.351 g/mol g·mol−1
3D model (JSmol)
  • NC(=O)CS(=O)C(c1ccccc1)c1ccccc1

Modafinil is a stimulant drug generally prescribed to treat narcolepsy, made by the pharmaceutical company Cephalon. It is not a typical stimulant and is often described as a "wakefulness promoting agent". The drug is sometimes prescribed off-label for Attention-Deficit Hyperactivity Disorder (ADHD). In mass-media advertisements and websites, Cephalon markets the drug for improving "alertness" and reducing excessive daytime sleepiness.

Commercial trade names

  • Provigil (US, UK, Italy, Belgium)
  • Vigil (Germany)
  • Modalert, Provake, Modapro, Modafil (India)
  • Modiodal (France, Mexico, Turkey, Greece, Sweden, Denmark, Portugal)
  • Modavigil (Australia)
  • Alertec (Canada)
  • Vigicer (Argentina)
  • Resotyl, Mentix, Alertex, Zalux (Chile)
  • Modasomil (Austria, Switzerland)
  • Vigia (Colombia)

Indications

In the United States, modafinil is approved by the FDA for the treatment of narcolepsy, obstructive sleep apnea/hypopnea and shift work sleep disorder. In some countries, it is also approved for idiopathic hypersomnia (all forms of excessive daytime sleepiness where causes can't be established).

Off-label use

Modafinil is widely used off-label to suppress the need for sleep. It is also used off-label in combating general fatigue unrelated to lack of sleep such as in treating ADHD and as an adjunct to antidepressants (particularly in individuals with significant residual fatigue). There is a disagreement whether the cognitive effects modafinil showed in healthy non-sleep-deprived people are sufficient to consider it to be a "cognitive enhancer."[2][3][4] The researchers agree that modafinil improves some aspects of working memory, such as digit span, digit manipulation and pattern recognition memory, but the results related to spatial memory, executive function and attention are equivocal.[2][3][4][5] Some of the positive effects of modafinil may be limited to "lower-performing"[5] individuals or to the individuals with lower IQ.[6] There is also evidence that it has neuroprotective effects.[7] Even though once a prescription drug is approved as safe and effective for a particular use, a physician may prescribe it for a different or off-label use, a drug manufacturer is prohibited from advertising it or promoting it for these off-label uses. Cephalon, the drugmaker of Provigil (modafinil) negotiated a plea bargain with the US Attorney in Philadelphia, and signed a corporate integrity agreement where it will admit to a misdemeanor violation of the Food, Drug and Cosmetic Act. The admission relates to its sales reps improperly marketing its narcolepsy approved drug (as well as some other drugs) for off-label uses such as depression and ADHD. Cephalon also had to pay a $425 million penalty.[8]

Doping agent

Modafinil has received some publicity in the past when several athletes were discovered allegedly using it as a doping agent. It is not clear how widespread this practice is. Since there are no studies pertaining to this sort of use, it is unknown whether modafinil can have any impact on an athlete's performance. However, anecdotal evidence indicates that modafinil does indeed enhance physical performance.

Modafinil was added to the World Anti-Doping Agency "Prohibited List" in 2004 as a prohibited stimulant.

In December 2007, professional poker player Paul Phillips claimed that the use of modafinil and other medications prescribed to him for ADHD treatment made him a much better player and helped him earn more than $2.3 million in poker. The drugs improved his concentration during high-stakes tournaments, he said, allowing him to better track all the action at his table.[9] In poker there are currently no rules prohibiting the use of stimulants.

Multiple sclerosis

Modafinil has been used to allay symptoms of the "neurological fatigue" reported by some with multiple sclerosis. Patients follow either the standard usage or take a single dose of 100–200 mg at the start of days self-assessed as being potentially excessively fatiguing. In 2000, Cephalon conducted a study to evaluate modafinil as a potential treatment for MS-related fatigue. A group of 72 people with MS of varying degrees of severity tested two different doses of modafinil and an inactive placebo over nine weeks. Fatigue levels were self-evaluated on standardized scales. Participants taking a lower dose of modafinil reported feeling less fatigued and there was a statistically significant difference in fatigue scores for the lower dose versus the placebo. The higher dose of modafinil was not reported to be effective.[10]

ADHD

As of February 2007, there are at least seven English-language articles on randomized clinical trials in humans in the Medline database addressing the use of modafinil for the treatment of attention deficit/hyperactivity disorder (ADHD). Some studies have shown the use of modafinil in the treatment of ADHD is associated with significant improvements in primary outcome measures. Cognitive function in ADHD patients was also found to improve following modafinil treatment, in some studies. Studies for ADHD report insomnia and headache were the most common adverse effects, seen in approximately 20% of treated individuals. These studies were not adequate to demonstrate that the beneficial effects of modafinil are maintained with chronic administration. Additional large, long-term studies using flexible titration methods to establish safety and efficacy and head-to-head comparisons between modafinil and stimulants are needed to determine the role of modafinil in the treatment of ADHD.[11]

In December of 2004, Cephalon submitted a supplemental new drug application (sNDA) to market Sparlon, a brand name of tablets containing higher doses of modafinil for the treatment of ADHD in children and adolescents ages 6 through 17. However, in March 2006, the FDA advisory committee voted 12 to 1 against approval, citing concerns about a number of reported cases of skin rash reactions in a 1000-patient trial, including one which was thought to be likely a case of Stevens-Johnson syndrome.[12][13] Final rejection occurred in August 2006, although subsequent follow-up indicated that the skin rash reaction was not Stevens-Johnson syndrome.[citation needed] Cephalon then decided to discontinue development of the Sparlon product for use in pediatric cases, though there is potential for use in treating Adult ADHD.

Modafinil is relatively contraindicated for patients with a history of cardiac events. However, one 2005 case report[14] positively describes transitioning a 78 year old with "significant cardiac comorbidity" from methylphenidate (5 mg b.i.d.) to modafinil; however, this was in the setting of severe treatment resistant depression, not ADHD. Thus, Modafinil's physiologic (and political) advantages over conventional ADHD therapies should not be dismissed out of hand, but rather discussed individually with a physician, neurologist or psychiatrist.

Other uses

Modafinil is also used off-label to treat sedation and fatigue in depression,[15][16] myotonic dystrophy,[17] opioid-induced sleepiness,[18] spastic cerebral palsy,[19] and Parkinson’s disease.[20] It increases subjective mood and friendliness, at least among shift workers.[21]

Experimental uses

Cocaine addiction

A single 8-week double-blind study of modafinil for cocaine dependence produced inconclusive results. The number of cocaine-positive urine samples was significantly lower in the modafinil group as compared to the placebo group in the middle of the trial, but by the end of the 8 weeks the difference stopped being significant. Even before the treatment began, the modafinil group had had lower cocaine consumption further confounding the results. As compared to placebo, modafinil did not reduce cocaine craving or self-reported cocaine use, and the physicians ratings were only insignificantly better.[22] In the polemics with the authors of the study, Dan Umanoff, of the National Association for the Advancement and Advocacy of Addicts, criticized them for leaving the negative results out of the discussion part and the abstract of the article.[23][24]

Weight loss

Studies on modafinil (even those on healthy weight individuals) indicate that it has an appetite reducing/weight loss effect.[25][21][26][27][28]All studies on modafinil in the Medline database that are for one month or longer which report weight changes find that modafinil users experience weight loss compared to placebo. .[29]

However, the prescribing information for Provigil notes that "There were no clinically significant differences in body weight change in patients treated with PROVIGIL compared to placebo-treated patients in the placebo-controlled clinical trials." [30]

In experimental studies, the appetite reducing effect of modafinil appears to be similar to that of amphetamines, but, unlike amphetamines, the dose of modafinil that is effective at decreasing food intake does not significantly increase heart rate.

Also, an article published in the Annals of Clinical Psychiatry, presented the case of a 280 pound patient (BMI=35.52) who lost 40 pounds over the course of a year on Modafinil (to 30.44 BMI). After three years, his weight stabilized at a 50 pound weight loss (29.59 BMI). The authors conclude that placebo controlled studies should be conducted on using Modafinil as a weight loss agent.[25]

Conversely, a U.S. patent (#6,455,588) on using modafinil as an appetite stimulating agent has been filed by Cephalon in 2000.

Primary biliary cirrhosis

Modafinil has been shown to improve excessive daytime somnolence and fatigue in primary biliary cirrhosis. After two months of treatment significant improvement was observed in symptoms of fatigue using the Epworth Sleepiness Scale.[31]

Post-chemotherapy cognitive impairment

Modafinil has been used off-label in trials with people with symptoms of Post-chemotherapy cognitive impairment, also known as chemobrain.[32] A University of Rochester study of 68 subjects had significant results. "We knew from previous studies that modafinil does alleviate problems with memory and attention, and were hoping it would do the same for breast-cancer patients experiencing chemo-brain, which it did," related the study's lead author Sadhna Kohli, Ph.D, a research assistant professor at the University of Rochester's James P. Wilmot Cancer Center.[33]

Contraindications and warnings

The literature advises that it is important to consult with your physician before using Modafinil, particularly for those with:

  • Hypersensitivity to the drug or other constituents of the tablets, or
  • Previous cardiovascular problems, particularly while using other stimulants, or
  • Cardiac conditions, particularly:

Severe adverse reactions

Modafinil may induce severe dermatologic reactions requiring hospitalization. From the date of initial marketing, December 1998, to January 30 2007, FDA received six cases of severe cutaneous adverse reactions associated with modafinil, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) involving adult and pediatric patients. The FDA issued a relevant alert. "Modafinil (marketed as Provigil): Serious Skin Reactions". FDA. Fall, 2007. {{cite web}}: Check date values in: |date= (help)

See the ADHD section for discussion of transitions to Modafinil from high dose stimulant regimens.

Patients with severe anxiety should be carefully supervised, as modafinil may exacerbate their condition. It may be necessary to coadminister an anxiolytic. High blood pressure should be stabilized before initiating treatment with modafinil or any other stimulant.

The patient should inform the prescribing physician of any other drugs they are currently taking, as modafinil may interact with a great number of drugs.

Relatively little is known regarding safety of modafinil during pregnancy or breastfeeding. Studies on pregnant rats and rabbits suggest that high doses of modafinil during pregnancy may increase the likelihood of birth defects. There are no adequate and well controlled trials with modafinil in pregnant women. Modafinil should only be used in pregnancy if the potential benefit for the mother justifies the potential risk to the fetus.

It is not known if modafinil or its metabolites are excreted in human milk. Caution should be exercised when modafinil is administered to a nursing woman.

Modafinil may reduce the effectiveness of contraceptives.

Alcohol and similar depressants should be avoided if at all possible while taking Modafinil.

Side-effects

The most common side-effects observed with modafinil, as compared to placebo, when prescribed in the recommended doses for the approved indications, are as follows:

Additionally, gastrointestinal distress, which may be alleviated by taking the drug after a meal, aggressiveness and skin irritation have been reported, but are rare.

Most side-effects subside after a few weeks without reducing the dose. Only headaches and anxiety have been shown to be proportional to dose, and these may benefit from a temporary reduction or dividing the dose.

A single case of premature ventricular contractions appeared causally linked to administration of modafinil.[34]

Modafinil may have an adverse effect on hormonal contraceptives, lasting for a month after cessation of dosage.[35]

Modafinil toxicity levels vary widely among species. In mice and rats, the median lethal dose LD50 of modafinil is approximately or slightly greater than 1250 mg/kg. Oral LD50 values reported for rats range from 1000 mg/kg to 3400 mg/kg. Intravenous LD50 for dogs is 300 mg/kg. In clinical trials on humans, taking up to 1200 mg/day for 7 to 21 days or one-time doses up to 4500 mg did not appear to cause life-threatening effects, although a number of adverse experiences were observed, including excitation or agitation, insomnia, anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, and diarrhea. As of 2004, FDA is not aware of any fatal overdoses involving modafinil alone (as opposed to multiple drugs, including modafinil).[36] Consequently, oral LD50 of modafinil in humans is not known exactly. However, it appears to be higher than oral LD50 of caffeine.

Military use

Militaries of several countries are known to have expressed interest in Modafinil as an alternative for amphetamine—the drug traditionally employed in sleep deprivation situations.

The French government indicated that the Foreign Legion used modafinil during certain covert operations. The United Kingdom's Ministry of Defence has admitted conducting ongoing research into Modafinil.[37] In the United States military, Modafinil has been approved for use on certain Air Force missions, and it is being investigated for other uses.[38]One study on helicopter pilots suggested that 600 mg of modafinil given in three doses can be used to keep pilots alert and maintain their accuracy at pre-deprivation levels for 40 hours without sleep.[39]However, significant levels of nausea and vertigo were observed. Another study of fighter pilots showed that modafinil given in three divided 100 mg doses sustained the flight control accuracy of sleep-deprived F-117 pilots to within about 27 percent of baseline levels for 37 hours, without any considerable side effects.[40] In an 88-hour sleep loss study of simulated military grounds operations, 400 mg/day doses were mildly helpful at maintaining alertness and performance of subjects compared to placebo, but the researchers concluded that this dose was not high enough to compensate for most of the effects of complete sleep loss.[41]

Pharmacology

The exact mechanism of action of Modafinil is unclear, although numerous in vitro studies have shown it to increase the levels of various monoamines, namely; dopamine in the striatum and nucleus accumbens,[42][43] noradrenalin in the hypothalamus and ventrolateral preoptic nucleus,[44][45] and serotonin in the amygdala and frontal cortex.[46] While the co-administration of a dopamine antagonist is known to decrease the stimulant effect of amphetamine, it does not negate the wakefulness-promoting actions of modafinil. Modafinil activates glutamatergic circuits while inhibiting GABAergic neurotransmission. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects.

The central stimulating effect of modafinil shows dose and time-related features. The effect tends to be enhanced by chlorination but reduced by methylation. Modafinil blocks the reuptake of norepinephrine by the noradrenergic terminals on sleep-promoting neurons from the ventrolateral preoptic nucleus (VLPO). Such a mechanism could be at least partially responsible for the wake-promoting effect of modafinil.

Modafinil has a binding coefficient (Ki) of about 4,000 nmol/L for the dopamine reuptake transporter, and in excess of 10,000 nmol/L for the norepinephrine reuptake transporter.

A newly proposed mechanism of action involves brain peptides called orexins, also known as hypocretins. Orexin neurons are found in the hypothalamus but project to many different parts of the brain, including several areas that regulate wakefulness. Activation of these neurons increases dopamine and norepinephrine in these areas, and excite histaminergic tuberomammillary neurons increasing histamine levels there. There are two receptors for hypocretins, namely hcrt1 and hcrt2. Animal studies have shown that animals with defective orexin systems show signs and symptoms similar to narcolepsy. Modafinil seems to activate these orexin neurons thus promoting wakefulness. However, a study of genetically modified dogs lacking orexin receptors showed that modafinil still promoted wakefulness in these animals, suggesting that orexin activation is not required for the effects of modafinil.

It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine and norepinephrine reuptake, as well as orexin activation.

It has been shown in rats that modafinil increases histamine release in the brain, and this may be a possible mechanism of action in humans.[47]

Modafinil used in a randomized double blind study showed that normal healthy volunteers between the ages of 30-44 showed general improvement in alertness as well as mood. In the 3 day study, counterbalanced, randomized, crossover, inpatient trial of modafinil 400 mg was administered as well as a placebo to the control group. The conclusion demonstrated that modafinil may have general mood elevating effects in particular for the adjunctive use in treatment-resistant depression.[31]

Armodafinil a single R-enantiomer of modafinil was approved by the FDA for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder.

Pharmacokinetics

Modafinil induces the cytochrome P450 enzymes CYP1A2, CYP2B6 and CYP3A4, as well as inhibiting CYP2C9 and CYP2C19 in vitro. It may also induce P-glycoprotein, which may affect drugs transported by Pgp, such as digoxin.

The bioavailabilty of Modafinil is greater than 80% of the administered dose. In vitro measurements indicate that 60% of Modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage actually changes very little when the concentration is varied.[48]

Cmax occurs approximately 2–3 hours after administration. Food will slow absorption, but does not affect the total AUC. Half-life is generally in the 10–12 hour range, subject to differences in CYP genotypes, liver function and renal function. It is metabolized in the liver, and its inactive metabolite is excreted in the urine. Urinary excretion of the unchanged drug ranges from 0% to as high as 18.7%, depending on various factors. [48]

History

Modafinil originated with the late 1970s invention of a series of benzhydryl sulfinyl compounds, also including adrafinil, by scientists working with the French pharmaceutical company Lafon. Adrafinil was first offered as an experimental treatment for narcolepsy in France in 1986. Modafinil is the primary metabolite of adrafinil and has similar activity but is much more widely used. It has been prescribed in France since 1994 under the name Modiodal, and in the US since 1998 as Provigil. It was approved for use in the UK in December 2002. Modafinil is marketed in the US by Cephalon Inc., who leased the rights from Lafon. Cephalon eventually purchased Lafon in 2001. In 2005, a petition by a private individual was filed with the FDA requesting over-the-counter sale of modafinil.[49]

Formulation patent

A U.S. patent 4,927,855 was granted to Lafon for modafinil in 1990. The FDA granted modafinil orphan drug status in 1993. The formulation patent expired on 30 March, 2006.

Particle size patent

Cephalon filed for U.S. patent 5,618,845, covering pharmaceutical compositions of modafinil, in 1994. That patent, granted in 1997, was reissued in 2002 as RE 37,516, which provides Cephalon with patent protection for certain preparations of the drug in the United States until 2014, which is now apparently extended to April 6 2015 after Cephalon received a six-month patent extension from the FDA.[50] However, a settlement in which Cephalon apparently paid out US$ 200 million to four generic drug manufacturers[51] may mean that generic forms of the drug will become available in April 2012 (October 2011 prior to the six month extension).

Some competing pharmaceutical manufacturers have applied to the FDA to market a generic form of modafinil in 2006. At least one withdrew their application after early opposition by Cephalon based on their new patent on particle sizes. There is some question as to whether a particle size patent is sufficient protection against the manufacture of generics. Pertinent questions include whether modafinil may be modified or manufactured to avoid the granularities specified in the new Cephalon patent, and whether patenting particle size is invalid because particles of appropriate sizes are likely to be obvious to practitioners skilled in the art.

Other wakefulness promoting agents

As of 2007, Modafinil does not have any significant competition. However, Vanda Pharmaceuticals, Inc. began Phase II clinical trials in 2007 for VSF-173, a drug that also targets excessive sleepiness.[52]

Modafinil is currently classified as a non-narcotic Schedule IV controlled substance under United States federal law; it is illegal to import by anyone other than a DEA-registered importer without a prescription.[53] Simple possession of Modafinil without a valid prescription is a felony that may be punishable by up to 1 year or more in prison. However, one may legally bring up to 50 dosage units (i.e. pills) of Modafinil to the United States in person from a foreign country, provided that he or she has a prescription for it, and the drug is properly declared at the border crossing.[54] Note that Adrafinil, a drug that is closely related to Modafinil, is currently not classified as a controlled substance, and therefore it is not as severely regulated.

The following countries do not classify Modafinil as a controlled substance:

Currently, use of modafinil is controversial in the sporting world, with high profile cases attracting press coverage as prominent United States athletes have tested positive for the substance. Some athletes who were found to have used modafinil protested that the drug was not on the prohibited list at the time of their offence. However, the World Anti-Doping Agency (WADA) maintains it was related to already banned substances. The agency added modafinil to the list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.

In the film The Invasion, Nicole Kidman is seen rummaging in a pharmacy for a stimulant. She grabs a bottle of "modifinil" 1 gram dosage. The common dosages for modafinil are 100 mg and 200 mg. The premise of the movie is that an alien virus works its evil during sleep so she needs to stay awake until she finds a cure.

In the television series Stargate SG-1, the season 10 episode "Morpheus" features the Stargate team infected by a disease which apparently caused a town to die in its sleep. The team struggles to stay awake and is provided with a variety of stimulants, as Colonel Mitchell takes out various bottles and reads their labels he finds one and reads "Modia... something", a likely reference to the European branding of Modafinil—Modiodal.

In the television series CSI: Crime Scene Investigation, the season 8 episode "Cockroaches" has CSI Warrick Brown suffering from stress related insomnia due to his divorce. He is shown taking a prescription for 100 mg modafinil to help him stay "alert" at work, but a co-worker becomes concerned that he is taking the pills too often and is taking them in conjunction with a prescription for sleeping pills (which are later referred to as Zolpidem).

In the Legacy of the Aldenata series of science fiction novels, the drug is referred to by the trade name Provigil and is used by military personnel in combination with a powerful stimulant to remain alert.

In the television series House, the season 2 episode "Forever" ends with a scene where Dr. Foreman is testing his memory with flash cards containing dosage information for various prescription drugs. After briefly giving up in frustration, he realizes Dr. Cameron saw him and decides to continue. Upon reading the next card, he smiles in triumph; the card is turned over to reveal the drug was modafinil.

See also

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003). "Cognitive enhancing effects of modafinil in healthy volunteers". Psychopharmacology (Berl.). 165 (3): 260–9. doi:10.1007/s00213-002-1250-8. PMID 12417966.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ a b Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM, File SE (2005). "Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?". J Clin Psychopharmacol. 25 (2): 175–9. PMID 15738750.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ a b Baranski JV, Pigeau R, Dinich P, Jacobs I (2004). "Effects of modafinil on cognitive and meta-cognitive performance". Hum Psychopharmacol. 19 (5): 323–32. doi:10.1002/hup.596. PMID 15252824.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ a b Müller U, Steffenhagen N, Regenthal R, Bublak P (2004). "Effects of modafinil on working memory processes in humans". Psychopharmacology (Berl.). 177 (1–2): 161–9. doi:10.1007/s00213-004-1926-3. PMID 15221200.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Randall DC, Shneerson JM, File SE (2005). "Cognitive effects of modafinil in student volunteers may depend on IQ". Pharmacol. Biochem. Behav. 82 (1): 133–9. doi:10.1016/j.pbb.2005.07.019. PMID 16140369.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Jenner, P (July 2000), "Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset", Experimental Brain Research, 133 (2): 178–188{{citation}}: CS1 maint: date and year (link)
  8. ^ [ http://www.fiercepharma.com/story/cephalon-pay-425m-settlement/2007-11-09]fiercepharma.com Cephalon pay 425 m settlement Nov 9, 2007 accessed Dec 11, 2007
  9. ^ Drugs to build up that mental muscle - Los Angeles Times
  10. ^ Rammohan, K W (2002), "Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study", Journal of Neurology Neurosurgery and Psychiatry, 72 (2): 179–183{{citation}}: CS1 maint: date and year (link)
  11. ^ Lindsay, SE (2006). "Use of modafinil for the treatment of attention deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 40 (10). Retrieved 2006-12-07. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  12. ^ "Psychopharmacologic Drugs Advisory Committee (transcript)". FDA. 2006-03-23.
  13. ^ "Modafinil (CEP-1538) Tablets Supplemental NDA 20-717/S-019 ADHD Indication Briefing Document for Psychopharmacologic Drugs Advisory Committee Meeting" (PDF). FDA. 2006-03-23. Retrieved 2007-07-21.
  14. ^ Xiong, M.D., Glen L. "Modafinil as an Alternative to Methylphenidate as Augmentation for Depression Treatment". Psychosomatics. 46. Academy of Psychosomatic Medicine: 578–579. doi:10.1176/appi.psy.46.6.578. Case report: Modafinil 200 mg daily replacing Methylphenidate 5 mg b.i.d in 78 year old cardiac patient {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ Menza, MA (2000), "Modafinil augmentation of antidepressant treatment in depression", J Clin Psychiatry, 61 (11): 378–381{{citation}}: CS1 maint: date and year (link)
  16. ^ DeBattista, C (2004), "A prospective trial of modafinil as an adjunctive treatment of major depression", J Clin Psychopharmacol, 24 (1): 87–90{{citation}}: CS1 maint: date and year (link)
  17. ^ MacDonald, JR (2002), "Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy", Neurology, 59: 1876–1880{{citation}}: CS1 maint: date and year (link)
  18. ^ Webster, L (June 2003), "Modafinil treatment of opioid-induced sedation", Pain Med, 4 (2): 135–140{{citation}}: CS1 maint: date and year (link)
  19. ^ Hurst, DL (March 2002), "Use of modafinil in cerebral palsy", J Child Neurology, 17 (3): 169–172{{citation}}: CS1 maint: date and year (link)
  20. ^ Nieves, AV (March 2002), "Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil", Clin. Neuropharmacol., 25 (2): 111–114{{citation}}: CS1 maint: date and year (link)
  21. ^ a b Hart, Carl (2006), "Modafinil attenuates disruptions in cognitive performance during simulated night-shift work.", Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology., 31 (7): 1526–1536{{citation}}: CS1 maint: date and year (link)
  22. ^ Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP (2005). "A double-blind, placebo-controlled trial of modafinil for cocaine dependence". Neuropsychopharmacology. 30 (1): 205–11. doi:10.1038/sj.npp.1300600. PMID 15525998.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ^ Umanoff DF (2005). "Trial of modafinil for cocaine dependence". Neuropsychopharmacology. 30 (12): 2298, author reply 2299–300. doi:10.1038/sj.npp.1300866. PMID 16294193.
  24. ^ Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP (2005). "Reply: Do Self-Reports Reliably Assess Abstinence in Cocaine-Dependent Patients?". Neuropsychopharmacology. 30 (12): 2299–300. doi:10.1038/sj.npp.1300867.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  25. ^ a b Henderson, David (April–June 2005), "Modafinil-Associated Weight Loss in a Clozapine-Treated Schizoaffective Disorder Patient", Annals of Clinical Psychiatry;, 17 (2): 95–97{{citation}}: CS1 maint: date and year (link) CS1 maint: extra punctuation (link)
  26. ^ Efficacy and Safety of Modafinil Film-Coated Tablets in Children and Adolescents
  27. ^ Vaishnavi, Sandeep (2006), "Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.", Journal of clinical psychopharmacology, 26 (4): 373–378{{citation}}: CS1 maint: date and year (link)
  28. ^ Michael, Thase (2006), "Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label extension study", CNS Spectrums, 11 (2): 93–101{{citation}}: CS1 maint: date and year (link)
  29. ^ Makris, Angela (April 2004), "Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity", Appetite, 42 (2): 185{{citation}}: CS1 maint: date and year (link)
  30. ^ 11613_Provigil_PI_4pgr_lo4.indd
  31. ^ a b Bonaventure, P., Letavic, M., Dugovich, C., Wilson, S., Alusio, L., Pudiak, C., et al. (2007, April 15). Histamine H(3) receptor antagonists: From target identification to drug leads. Biochemical Pharmocology, 73(2007 Apr 15; Vol. 73 (8), pp. 1084–96), 1084–96. Abstract retrieved April 2, 2007, from Medline database.
  32. ^ "Doctors are finding it harder to deny 'Chemobrain'", The Virginian-Pilot, © October 2, 2007.
  33. ^ Modafinil Relieves Cognitive Chemotherapy Side Effects Psychiatric News, Stephanie Whyche, August 3, 2007 Volume 42 Number 15, page 31
  34. ^ Oskooilar, Nader (2005). "A Case of Premature Ventricular Contractions With Modafinil". American Journal of Psychiatry. 162: 1983-a-1984. doi:10.1176/appi.ajp.162.10.1983-a. {{cite journal}}: Unknown parameter |month= ignored (help)
  35. ^ "MedlinePlus Drug Information: Modafinil". NIH. 2005-07-01. Retrieved 2007-07-21.
  36. ^ "FDA Approved Labeling Text for Provigil" (PDF). FDA. 2004-01-23.
  37. ^ BBC report on MoD research into Modafinil
  38. ^ Modafinil and Management of Aircrew Fatigue - United States Air Force memo
  39. ^ The Effects of Modafinil on Aviator Performance During 40 Hours of Continuous Wakefulness
  40. ^ The efficacy of Modafinil for sustaining alertness and simulator flight performance in F-117 pilots during 37 hours of continuous wakefulness
  41. ^ http://stinet.dtic.mil/cgi-bin/GetTRDoc?AD=ADA454558&Location=U2&doc=GetTRDoc.pdf A Double-Blind Placebo-Controlled Investigation of the Efficacy of Modafinil for Maintaining Alertness and Performance in Sustained Military Ground Operations
  42. ^ Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. "Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants." European Journal of Pharmacology 2007 Jul 30;568(1-3):112-23. Epub 2007 Apr 5. PMID: 17477916
  43. ^ Murillo-Rodríguez E, Haro R, Palomero-Rivero M, Millán-Aldaco D, Drucker-Colín R. "Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats." Behavioral Brain Research 2007 Jan 25;176(2):353-7. Epub 2006 Nov 13. PMID: 17098298.
  44. ^ de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. "Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats." Neuroreport 2001 Nov 16;12(16):3533-7. PMID: 11733706.
  45. ^ Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. "Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study." Sleep 2004 Feb 1;27(1):19-25. PMID: 14998233.
  46. ^ Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T. "Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression." Journal of Neuroscience Research 2002 Apr 1;68(1):107-12. PMID: 11933055.
  47. ^ Ishizuka, T (2003). "Modafinil increases histamine release in the anterior hypothalamus of rats". Neuroscience Letters. 339 (2): 143–6. PMID 12614915. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  48. ^ a b Hardman, Joel and Limbird, Lee. 2001. "Goodman and Gilman’s: The Pharmacological Basis of Therapeutics." Edition 10. pp 1984t. New York: McGraw-Hill.
  49. ^ "Dockets Entered On December 26, 2006". FDA. 2006-12-26. Retrieved 2007-07-21. 2005P-0265 Over-the Counter Sale of Modafinil
  50. ^ "Cephalon gets six-month Provigil patent extension". Philadelphia Business Journal. 2006-03-28. Retrieved 2007-07-21.
  51. ^ Pringle, Evelyn (2006-03-20). "Sparlon: Just What Kids Need - Another ADHD Drug". Retrieved 2007-07-21.
  52. ^ "www.vandapharma.com/development.html".
  53. ^ "Is It Illegal to Obtain Controlled Substances From the Internet?". United States Drug Enforcement Administration. Retrieved 2007-07-21.
  54. ^ "USC 201 Section 1301.26 Exemptions from import or export requirements for personal medical use". United States Department of Justice. 1997-03-24.
  55. ^ "Regulations Amending the Food and Drug Regulations (1184 — Modafinil)". Canada Gazette. 140 (20). 2006-10-04.
  56. ^ "Estupefacientes y Psicotrópicos" (in Spanish). Comisión Federal para la Protección contra Riesgos Sanitarios. Retrieved 2007-07-21.
  57. ^ Julia Llewellyn Smith (2004-01-06). "The 44-hour day". The Telegraph.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Modafinil&oldid=204542178"